China's Big Cities Should Be First Priority For Pharma Companies - IMS
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI- China's largest cities control the majority of the Chinese pharma market, and companies must decide city-specific sales strategies, according to the global healthcare data provider and consulting firm IMS Health
You may also be interested in...
Expansion Into China's Lower-Tier Cities Could Be Growth Driver For Big Pharma
China's smaller cities are emerging rapidly as growth areas, while Big Pharma is still focused mostly on Tier 1 cities such as Shanghai, Beijing and Guangzhou, according to IMS Health.
Expansion Into China's Lower-Tier Cities Could Be Growth Driver For Big Pharma
China's smaller cities are emerging rapidly as growth areas, while Big Pharma is still focused mostly on Tier 1 cities such as Shanghai, Beijing and Guangzhou, according to IMS Health.
Expansion Into China's Lower-tier Cities Could Be Growth Driver For Big Pharma
SHANGHAI - China's pharma market is expected to continue to grow in the next five years with a CAGR of 23.2%, which will be backed largely by the expansion of community health centers across tier 2 and tier 3 cities, according to a report issued by consultancy IMS Health